Publication:
Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: routine testing is indicated

dc.contributor.coauthorXue, Yue
dc.contributor.coauthorBalci, Serdar
dc.contributor.coauthorJiang, Hongmei
dc.contributor.coauthorPehlivanoglu, Burcin
dc.contributor.coauthorMuraki, Takashi
dc.contributor.coauthorMemis, Bahar
dc.contributor.coauthorSaka, Burcu
dc.contributor.coauthorKim, Grace E.
dc.contributor.coauthorBandopadhyay, Sudeshna
dc.contributor.coauthorKnight, Jessica
dc.contributor.coauthorEl-Rayes, Bassel F.
dc.contributor.coauthorSarmiento, Juan
dc.contributor.coauthorReid, Michelle D.
dc.contributor.coauthorBasturk, Olca
dc.contributor.departmentN/A
dc.contributor.kuauthorMeriçöz, Çisel Aydın
dc.contributor.kuauthorTaşkın, Orhun Çığ
dc.contributor.kuauthorAdsay, Nazmi Volkan
dc.contributor.kuauthorErkan, Murat Mert
dc.contributor.kuprofileTeaching Faculty
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileFaculty Member
dc.contributor.researchcenterKoç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM)
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid162418
dc.contributor.yokid166686
dc.contributor.yokid286248
dc.contributor.yokid214689
dc.date.accessioned2024-11-09T22:45:33Z
dc.date.issued2020
dc.description.abstractBackground: The significance of DNA mismatch repair (MMR) deficiency in ampullary cancers (ACs) has not been established. Methods In total, 127 ACs with invasive carcinomas measuring >= 3 mmthat had adequate tissue were analyzed immunohistochemically. Results: MMR loss was detected in 18% of ACs (higher than in colorectal cancers). Twelve tumors with MLH1-PMS2 loss were negative forBRAF V600Emutation, suggesting a Lynch syndrome association. MMR-deficient tumors (n = 23), comparedwith MMR-intact tumors (n = 104), showed a striking male predominance (male:female ratio, 4.7). Although the deficient tumors had slightly larger invasion size (2.7 vs 2.1 cm), they also had more expansile growth and less invasiveness, including less perineural invasion, and they ultimately had lower tumor (T) classification and less lymph node metastasis (30% vs 53%;P = .04). More important, patients who had MMR-deficient tumors had better clinical outcomes, with a 5-year overall survival rate of 68% versus 45% (P = .03), which was even more pronounced in those who had higher Tclassification (5-year overall survival, 69% vs 34%;P = .04). MMR deficiencyhad a statistically significant association with medullary phenotype, pushing-border invasion, and tumor-infiltrating immune cells, and it occurred more frequently in ampullary-duodenal type tumors. Programed cell death-ligand 1 (PD-L1) levels analyzed in the 22 MMR-deficient ACs revealed that all medullary carcinomas were positive. Nonmedullary MMR-deficient carcinomas expressed PD-L1 in 33% of tumors cells according to the criteria for a combined positive score >= 1, but all were negative according to the tumor proportion score >= 1 method. Conclusions: In ACs, MMR deficiency is even more frequent (18%) than in colon cancer and often has a Lynch-suggestive profile, thus routine testing is warranted. Male gender, pushing-border infiltration, ampullary-duodenal origin, medullary histology, and tumor-related inflammation have a significantly higher association with MMR deficiency. MMR-deficient tumors have less aggressive behavior. PD-L1 expression is common in medullary-phenotype ACs, thus immunotherapy should be considered at least for this group.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue21
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.volume126
dc.identifier.doi10.1002/cncr.33135
dc.identifier.eissn1097-0142
dc.identifier.issn0008-543X
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85089891240
dc.identifier.urihttp://dx.doi.org/10.1002/cncr.33135
dc.identifier.urihttps://hdl.handle.net/20.500.14288/6114
dc.identifier.wos563291700001
dc.keywordsAmpullary carcinoma
dc.keywordsMedullary carcinoma
dc.keywordsMismatch repair
dc.keywordsProgrammed cell death-ligand 1
dc.keywordsTumor-infiltrating inflammation
dc.languageEnglish
dc.publisherWiley
dc.sourceCancer
dc.subjectOncology
dc.titleFrequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: routine testing is indicated
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-4541-793X
local.contributor.authorid0000-0002-6668-3006
local.contributor.authorid0000-0002-1308-3701
local.contributor.authorid0000-0002-2753-0234
local.contributor.kuauthorMeriçöz, Çisel Aydın
local.contributor.kuauthorTaşkın, Orhun Çığ
local.contributor.kuauthorAdsay, Nazmi Volkan
local.contributor.kuauthorErkan, Murat Mert

Files